For the Inventor, By the Inventor

Enter assignee name

Newton, MA, United States of America

Karyopharm Therapeutics Inc.

USPTO Granted Patents = 39

CIPO Patents = 1

EPO Patents = 11

Trademarks = 9

Forward Citations = 536

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Sharon Shacham (29 out of 50 patents)

Sharon Shechter (27 out of 36 patents)

Dilara McCauley (26 out of 43 patents)

4. Erkan Baloglu (19 out of 34 patents)

5. Vincent Premaratna Sandanayaka (17 out of 41 patents)

6. William Senapedis (12 out of 12 patents)

7. Ori Kalid (10 out of 12 patents)

8. Yosef Landesman (10 out of 10 patents)

9. Gali Golan (10 out of 10 patents)

10. Brian C Austad (7 out of 31 patents)

11. David Gregory Roe (7 out of 27 patents)

12. Trinayan Kashyap (4 out of 4 patents)

13. Michael Kauffman (3 out of 3 patents)

14. Tami Rashal (1 out of 1 patent)

15. Jean-Richard Saint-Martin (1 out of 1 patent)

39 patents: Sort by Forward Citations

1. 12479806 - Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XPO1 inhibitors (2025-11-25),

2. 12371420 - Polymorphs of Selinexor (2025-07-29),

3. 12331040 - Substituted benzofuranyl and benzoxazolyl compounds and uses thereof (2025-06-17),

4. 12318386 - Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer (2025-06-03),

5. 12291508 - Hydrazide containing nuclear transport modulators and uses thereof (2025-05-06),

6. 11945794 - Nuclear transport modulators and uses thereof (2024-04-02),

7. 11807629 - Polymorphs of Selinexor (2023-11-07),

8. 11787771 - Hydrazide containing nuclear transport modulators and uses thereof (2023-10-17),

9. 11753401 - Polymorphs of Selinexor (2023-09-12),

10. 11746102 - Polymorphs of selinexor (2023-09-05),

11. 11124493 - Nuclear transport modulators and uses thereof (2021-09-21),

12. 11078190 - Polymorphs of selinexor (2021-08-03),

13. 11034660 - Hydrazide containing nuclear transport modulators and uses thereof (2021-06-15),

14. 11008309 - Substituted benzofuranyl and benzoxazolyl compounds and uses thereof (2021-05-18),

15. 10858347 - Multicyclic compounds and uses thereof (2020-12-08),

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel drugs targeting various types of cancer. With a range of proprietary technology platforms, Karyopharm aims to develop innovative therapies that address unmet medical needs and improve the lives of patients. The company's pipeline includes potential treatments for multiple myeloma, acute leukemias, and solid tumors. Karyopharm Therapeutics is committed to advancing science and bringing forward new treatment options in oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

39 Patents

#6 in Newton, MA

#497 in Massachusetts

#8,539 in US

#16,943 in the World

Newton, MA, United States of America

Karyopharm Therapeutics Inc.

Forward Citations = 536

15 inventors:

Sharon Shacham (29 out of 50 patents)

Sharon Shechter (27 out of 36 patents)

Dilara McCauley (26 out of 43 patents)

4. Erkan Baloglu (19 out of 34 patents)

5. Vincent Premaratna Sandanayaka (17 out of 41 patents)

Please report any incorrect information to support@idiyas.com

Loading…